STAAR Surgical Showcases EVO ICL Innovation and Clinical Insights - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

STAAR Surgical Showcases EVO ICL Innovation and Clinical Insights

Expanded indications, surgeon-led education, and new clinical research highlight STAAR Surgical’s presence at the ESCRS Congress

  • September 11, 2026

  • 3 min

Share

  • 1

    STAAR Surgical will showcase its EVO ICL technology at the 44th ESCRS Congress in London from September 11–15, 2026.

  • 2

    Over four million EVO ICLs have been sold globally, with CE Mark approval received in Europe in 2011.

  • 3

    EVO ICL indications have expanded to include patients up to 60 years and as a supplemental lens after cataract surgery.

  • 4

    EVO Insights LIVE will feature small-group sessions addressing practical topics in EVO ICL management for surgeons.

  • 5

    The EVO ICL is made from proprietary Collamer® material, offering optical quality and compatibility without corneal tissue removal.

Original Source(s)

STAAR Surgical Showcases EVO ICL Innovation and Clinical Insights

  • September 11, 2026

Related Content

Expanding visual horizons: comparative outcomes of bilateral implantation of an extended depth-of-focus versus enhanced and standard monofocal intraocular lenses

Dead bag syndrome may present asymmetrically

Spontaneous posterior capsular rupture affected both eyes years following uncomplicated cataract surgery, but intraocular lens dislocation required surgery in only 1 eye.

JIA-Associated Uveitis in Adults

Ophthalmologists caring for adults with this condition may encounter persistent inflammation, treatment dependence, and the cumulative ocular effects of childhood disease.